Synergy CHC: strong margins and profit but burdened by $17.5M loan, high interest, weak controls

Snapshot - Synergy CHC Corp. (OTCBB: SNYR)

What's happening inside: management is actively reshaping the balance sheet and funding profile. In May-June 2025 the company drew a $17.5M secured term loan, used proceeds to retire prior debt, issued equity/warrants to settle lenders, and recognized a large non-cash gain on loan settlements. Operations generated solid gross margins, but interest costs and legacy debt restructuring dominate the headlines. Management flags disclosure-control weaknesses even as it says near-term liquidity is adequate.

Key facts & statistics (from Q2 / six months ended June 30, 2025)
* Total revenue (Q2): $8,134,996 - Product Sales $6,734,996; License Revenue $1,400,000.
* Six-month revenue: $16,305,530 (Product $13,405,530; License $2,900,000).
* Gross profit (Q2): $6,238,605 - gross margin 77% (six months: $12,402,626, 76%).
* Net income (Q2): $1,473,237; six months: $2,349,501.
* Net income per share - basic/diluted (Q2): $0.17; six months: $0.27.
* EBITDA (Q2): $3,804,013; six months: $5,783,637 (company non‑GAAP measure).
* Interest expense (Q2): $2,107,714; six months: $3,203,083 (material increase year‑over‑year).
* Gain on settlement of notes payable (non‑cash): $(2,154,522) in Q2 and six months (reduced reported other expense).
* Cash and restricted cash (6/30/25): $1,558,561 ($1,458,561 cash + $100,000 restricted).
* Accounts receivable, net: $9,094,983 (Trade $7,069,889; Other $2,025,094). Two customers = 84% of trade receivables.
* Inventory: $2,364,158.
* Total assets: $19,726,346; Total liabilities: $32,105,546.
* Stockholders' deficit: $(12,379,200); accumulated deficit: $(41,750,312).
* Working capital surplus (management): $12,383,132 (management cites as alleviating going‑concern doubts).
* Major financing actions: $17,500,000 May 2025 loan (Term SOFR + 8.5%, maturity 2029); $15M initial draw + $2.5M delayed draw; $2,355,914 recorded as original debt discount; unamortized debt issuance cost and debt discount on notes payable: $(2,387,309).
* Shares issued / equity settlements: pre‑funded warrants issued and exercised (428,570) and shares issued (441,178) as part of debt settlements; issued 30,360 shares for loan facilitation fees.

Positive aspects (income statement & operations)
* Strong gross margins: 77% (Q2) and 76% (six months) driven by low cost of sales and one-time license revenue recognition.
* Company reported positive net income and positive EPS both quarter and YTD (Q2 net income $1.47M; EPS $0.17).
* EBITDA expansion vs prior year (Q2 EBITDA $3.80M vs $1.61M a year earlier) - operating profitability improved on a headline basis.
* License revenue ($1.4M Q2; $2.9M six months) is accretive and lifts margins without incremental COGS.

Negative aspects & risks (income statement, balance sheet, disclosure)
* Very high interest expense: $2.11M (Q2) and $3.20M (six months) - interest is a recurring cash drain and grew materially vs prior year.
* Reported net income is materially impacted by a non‑cash gain on debt settlement of $(2.15M) - operating cash flow remains negative (net cash used in operating activities: $(899,731) six months).
* Large leverage and negative equity: Total liabilities $32.11M vs assets $19.73M; stockholders' deficit $(12.38M).
* Customer concentration: three customers ≈ 80% of net revenue (six months) and two customers account for 84% of trade receivables - revenue and collections risk are concentrated.
* Receivables heavy: $9.09M accounts receivable vs $1.46M cash - liquidity tied up in receivables.
* Debt economics and covenants: new $17.5M secured loan carries high spread (SOFR + 8.5%); covenant schedule (senior net leverage ratio and fixed charge coverage) could restrict flexibility.
* Controls weakness: CEO and CFO concluded disclosure controls and procedures are not effective - increased reporting risk and potential for surprises.
* Valuation/usage of NOLs: ~$48.7M NOLs on the books but 100% valuation allowance taken - unlikely to be realized per management.

Operational/finance action items and what to watch next
* Collections and DSO: monitor accounts receivable aging and cash conversion - $7.07M trade receivables are a pressure point.
* Covenant compliance: track quarterly covenant metrics tied to the May 2025 loan (consolidated senior net leverage and fixed charge coverage).
* Interest and amortization schedule: watch effective interest cash out (interest paid YTD reported; supplemental shows cash interest paid $896,734 in period).
* Customer diversification: success expanding online channel (online sales grew to $4.84M six months) vs retail declines - diversification progress matters.
* Disclosure control fixes: any remediation timelines or independent reviews from auditors/regulators.
* Use of proceeds from the May loan and any additional draws on delayed/incremental facilities; further debt/equity settlements.

Bottom line
Synergy CHC shows improved headline profitability and very strong gross margins (helped by license income and debt-settlement gains), but the cash story is mixed: operating cash used, high receivables concentration, heavy new secured debt with steep economics, and persistent negative equity. The company's near-term survival appears supported by the May 2025 financing and working‑capital claims from management - but execution on collections, covenant compliance and disclosure-control remediation will determine whether the operational improvements convert into sustainable shareholder value.

Sources: Synergy CHC Corp. Condensed Consolidated Financial Statements and MD&A - Form 10‑Q for period ended June 30, 2025.